Antiviral drug

Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir

Wednesday, July 28, 2021 - 1:57pm

New York, NY, and Tel Aviv, ISRAEL, July 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has retained the services of Innvocept Global Solutions, an Indian clinical research organization (CRO), to manage 2 adaptive design Phase 2/3 clinical trials the Company is preparing to initiate with its joint venture partner NLC Pharma of its proprietary oral antiviral 3CL protease inhibitor drug candidate Tollovir™ for the treatment of non-hospitalized and hospitalized COVID-19 patients in India. Engaging a CRO is the first step of the regulatory process in India.  The Company expects enrollment for both trials to begin in the third quarter of 2021 with initial, trial expansion-enabling data expected in the fourth quarter of 2021 that could make each trial become part of the Company’s global pivotal clinical development program for Tollovir that would begin in the fourth quarter of 2021.

Key Points: 
  • This trial opened enrollment in April 2021 and is also evaluating the use of TolloTest as a companion diagnostic for antiviral therapy.
  • TolloTest is the Companys proprietary 3CL protease biomarker assay that is being developed as a more accurate measure of viral infection, load and infectiousness in COVID-19 patients.
  • This dual mechanism makes Tollovir unique among the emerging class of 3CL protease inhibitors currently in development.
  • For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials.

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Tuesday, July 27, 2021 - 1:09pm

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1

Monday, July 26, 2021 - 12:05pm

This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study.

Key Points: 
  • This trial builds on the encouraging results from the Companys previously completed IMC-1 phase 2a FM clinical study.
  • This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication.
  • The Company anticipates reporting top line results from the currently enrolling FORTRESS Phase 2b FM trial in mid-2022.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

Israeli start-up ONYX radiance launches Covid-19 eliminating and skin-rejuvenating face mask

Monday, July 26, 2021 - 3:00pm

The Antiviral Defense Mask maintains its efficiency in destroying >99% of the Covid-19 virus, Influenza virus, and bacteria,after50 regular home laundries.

Key Points: 
  • The Antiviral Defense Mask maintains its efficiency in destroying >99% of the Covid-19 virus, Influenza virus, and bacteria,after50 regular home laundries.
  • The Anti-viral results have been verified by a qualified independent laboratory in accordance with the ISO18184 test protocol.
  • ONYX radiance eyes on becoming a global leading technological consumer textile brand of high-end textile products that provide its users with substantial Health & Beauty benefits.
  • Customers of ONYX radiance are continuously reporting on significant improvement in their skin's health and appearance, on alleviation of severe Acne conditions, and on much improved sleep quality.

JBS Couros launches antiviral leather

Thursday, July 22, 2021 - 7:00pm

SÃO PAULO, July 22, 2021 /PRNewswire/ -- JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19. At processing stage, a silver microparticle additive is added to the leather coating   providing it with antiviral qualities.

Key Points: 
  • SO PAULO, July 22, 2021 /PRNewswire/ --JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19.
  • At processing stage, a silver microparticle additive is added to the leather coating providing it with antiviral qualities.
  • "Our leather has undergone scientific tests that prove the inactivation of the SARS-Cov-2 virus.
  • "The use of this technology increases the contact surface of silver and its prominence in the leather, enabling antiviral action," says researcher Lucio Freitas, who participated in the tests of the new material.

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives

Thursday, July 22, 2021 - 1:00pm

We are thrilled to see that our Anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.

Key Points: 
  • We are thrilled to see that our Anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.
  • The U.S. pharma industry has shouldered the responsibility of developing and manufacturing some of the worlds most innovative and best-selling drugs.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19

Wednesday, July 14, 2021 - 12:30pm

QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses.

Key Points: 
  • QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses.
  • We are excited to have reached this important milestone of submitting our first IND application to the FDA on our most advanced therapeutics program.
  • Viruses such as SARS-CoV-2 exploit nucleolin to gain access to a cell and manipulate it for its own viral replication purposes.
  • STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds.

Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses

Tuesday, July 13, 2021 - 5:04am

DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents.

Key Points: 
  • DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents.
  • The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses.
  • The DODs Defense Threat Reduction Agencys Chem Bio Technologies, Vaccines and Therapeutics Division executed an Other Transaction Authority (OTA) agreement with Evrys for this effort.
  • EVRYS stands for the Companys vision to ultimately address every virus, said Lillian Chiang, PhD, CEO, Evrys Bio.

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

Friday, July 9, 2021 - 12:25pm

OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

Key Points: 
  • OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.
  • In an HCT, subjects are intentionally exposed to particular diseases to test how the diseases will respond to potential therapeutics.
  • This Phase 2a study will come in the wake of AIMs recent announcement that all subjects have completed treatment in the companys Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

COVID-19 Treatment Clinical Landscape Research Report 2021 - ResearchAndMarkets.com

Friday, July 9, 2021 - 11:35am

The "Disease Analysis: COVID-19 Treatment" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: COVID-19 Treatment" report has been added to ResearchAndMarkets.com's offering.
  • The commercial outlook for COVID-19 therapeutics is expected to decline progressively throughout 2021 due to the phased implementation of global vaccination programs, which should substantially reduce both outpatient and hospital COVID-19 cases.
  • Veklury faces myriad threats from pipeline candidates, including antivirals, immunomodulatory agents, monoclonal antibodies, and hyperimmune globulin therapies.
  • The overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a drug advances from Phase III is 68.5%.